Trending...
- YieldOMega Launches $DOUB Airdrop Campaign Ahead of TimeCurve Launch
- Brewtay Coffee Partners with Alex's Lemonade Stand to Fuel Penn Wynne Volunteers
- AI Is Closing the Gap Between Offshore Virtual Assistants and Onshore Staff
PHILADELPHIA--(BUSINESS WIRE)--iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM will produce and supply Good Manufacturing Practices (GMP)-grade adeno-associated virus (AAV) for use in iECURE's future clinical studies to enable development of iECURE's programs with the shared mission of accelerating the availability of these potential treatments to the patients.
"Our approach to gene editing relies on highly complex manufacturing processes, and we are eager to establish partnerships to ensure a reliable supply of GMP materials for future clinical development," said Paul Firuta, Chief Operating Officer of iECURE. "CBM was able to offer us significant amount of guaranteed capacity with scheduling flexibility and we are confident that they will be a strong partner with their state-of-the-art facilities and end-to end capabilities."
More on The PennZone
"iECURE's approach to gene editing is quite innovative and has the potential to bring significant hope to patients and families facing devastating diagnoses," said Audrey Greenberg, Chief Business Officer and Co-Founder of CBM. "Our ability to provide customizable clinical and commercial GMP manufacturing solutions integrated with industry-leading comprehensive in-process testing, quality control, and lot release programs allows us to support our partners like iECURE through the entirety of their product lifecycle and is aligned with our mission to bring life changing medicines to patients in need."
About iECURE
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of monogenic liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team's core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania's Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP's world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates. For more information, visit www.iecure.com and follow on LinkedIn.
More on The PennZone
About Center for Breakthrough Medicines (CBM)
CBM is a cell and gene therapy contract development and manufacturing organization (CDMO) based in the heart of Philadelphia's Cellicon Valley. CBM offers pre-clinical through commercial manufacturing capabilities including process development, plasmid DNA, viral vector, cell therapy and a full suite of testing and analytical capabilities. Through a single-source, end-to-end solution, CBM accelerates time to market without compromising quality.
Contacts
Investors:
David Garrett
dgarrett@iecure.com
Media:
Danielle Cantey
Canale Communications
danielle.cantey@canalecomm.com
"Our approach to gene editing relies on highly complex manufacturing processes, and we are eager to establish partnerships to ensure a reliable supply of GMP materials for future clinical development," said Paul Firuta, Chief Operating Officer of iECURE. "CBM was able to offer us significant amount of guaranteed capacity with scheduling flexibility and we are confident that they will be a strong partner with their state-of-the-art facilities and end-to end capabilities."
More on The PennZone
- Vinnie Rocco Opens AgentiX Minds To Help Business Owners & Execs Learn AI Agents
- Color Card Administrator Highlights Growing Enterprise Demand for Operational Infrastructure in Business Card Identity Governance
- American Properties Celebrates Grand Opening and Ribbon Cutting Ceremony at Heritage at South
- MoMojo Records signs Arlen Roth; "Blues Grass" slated for August 7, 2026 release
- Crosswalk Ministries USA Announces 2026 Child and Family Well-Being Conference in Stockbridge, Georgia
"iECURE's approach to gene editing is quite innovative and has the potential to bring significant hope to patients and families facing devastating diagnoses," said Audrey Greenberg, Chief Business Officer and Co-Founder of CBM. "Our ability to provide customizable clinical and commercial GMP manufacturing solutions integrated with industry-leading comprehensive in-process testing, quality control, and lot release programs allows us to support our partners like iECURE through the entirety of their product lifecycle and is aligned with our mission to bring life changing medicines to patients in need."
About iECURE
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of monogenic liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team's core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania's Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP's world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates. For more information, visit www.iecure.com and follow on LinkedIn.
More on The PennZone
- Autism Podcast Helps Parents Understand Why Behavior Is Communication, Not Defiance
- Filmmaker Preston A. Dent to Premiere "Harrisburg-The Movie" at Whitaker Center for the Arts
- Pollock Begg Family Law Attorneys Earn 2026 Pennsylvania Super Lawyers Honors at Every Level
- Research reveals "The Borderless Pay Standard," a 48-point gap between multinational employers and workers on transparent pay expectations
- Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
About Center for Breakthrough Medicines (CBM)
CBM is a cell and gene therapy contract development and manufacturing organization (CDMO) based in the heart of Philadelphia's Cellicon Valley. CBM offers pre-clinical through commercial manufacturing capabilities including process development, plasmid DNA, viral vector, cell therapy and a full suite of testing and analytical capabilities. Through a single-source, end-to-end solution, CBM accelerates time to market without compromising quality.
Contacts
Investors:
David Garrett
dgarrett@iecure.com
Media:
Danielle Cantey
Canale Communications
danielle.cantey@canalecomm.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Robert J. Bradshaw's AYE is a Gripping Dual Reality Thriller Exploring the Increasingly Blurred Line Between Humanity and Technology
- Bangxing Silicone Revolutionizes Silicone Baby Product Partnerships: Low MOQ Support + VIP Long-Term Win-Win Programs
- JFAB Consulting Elevates Brand with New Identity and Digital Experience
- SteelTree Announces Launch of Its Operational Decision Intelligence Service
- Advanced AI Capabilities Reflected by Upcoming Company Name and Stock Symbol Change for Evolving Pre-Owned Boat Dealer: Off The Hook YS: N Y S E: OTH
- AI-Driven Defense Expansion, Autonomous Systems and Israeli Aerospace Manufacturing Platform: VisionWave Holdings (N A S D A Q: VWAV)
- AI Predicts the Most Likely 2026 FIFA World Cup Winner
- The AI Production Shift: Why Game Development Is Entering Its Most Accelerated Phase
- World-First AI Humanoid Robot Debuts on Cherie Barber's Ground-breaking Australian Reno Show
- New Survey Reveals America's Most Feared Bridges for Cyclists — Golden Gate Tops the List
- Raymond Lavine, Extended Care Benefits Advisor and Author, to Appear on National Television Series Moving America Forward
- NaturismRE Launches Structured Nudism & Naturism Encyclopedia, Aiming to Reframe Public Understanding
- AiBT Advisory Launches AI Deployment Firm for the Mid-Market Companies Big AI Left Behind
- AI Is Closing the Gap Between Offshore Virtual Assistants and Onshore Staff
- CCHR Highlights Concerns Over Coercive and Failed $140 Billion Mental Health Practices at Psychiatric Convention
- Avery Headley Leads Major Stabilization and Modernization Initiative Across Bronx Affordable Housing Portfolio
- NewReputation's AI Sentiment Analysis Tool Reaches 2,500 Users as Businesses Demand Clearer Brand Intelligence
- CAPO Supply Announces Opening of Second Location in New Castle, Pennsylvania
- $224 Billion Growing Market in Life Settlements Presents Major Opportunity for New Policy Acquisition Business Plan: DLT Resolution Stock Symbol: DLTI
- Fyt-02 Launches on Kickstarter The Smart Sensor That Turns Any Chair Into a Posture & Movement Track